The association between antenatal exposure to selective serotonin reuptake inhibitors and autism: A systematic review and meta-analysis

Journal of Clinical Psychiatry

Volumn 78, Issue 1, 2017, Pages e48-e58

  Brown, Hilary K ^a,b   Hussain Shamsy, Neesha ^a   Lunsky, Yona ^b,c   Dennis, Cindy Lee E ^a,b   Vigod, Simone N ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antidepressants; Autism; Women's mental health

Indexed keywords

SEROTONIN UPTAKE INHIBITOR;

AUTISM; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; FIRST TRIMESTER PREGNANCY; HUMAN; MATERNAL MENTAL ILLNESS; MENTAL DISEASE; PRENATAL EXPOSURE; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; AUTISM SPECTRUM DISORDER; CHEMICALLY INDUCED; CHILD; DEPRESSIVE DISORDER; FEMALE; INFANT; META ANALYSIS; NEWBORN; OBSERVATIONAL STUDY; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PRESCHOOL CHILD;

AUTISM SPECTRUM DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 85012916973     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15r10194     Document Type: Review

References (48)

1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
2. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years-Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2010. MMWR Surveill Summ. 2014;63(2):1-21.
3. Harrington RA, Lee LC, Crum RM, et al. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 2013;6(3):149-168.
4. Andrade SE, Raebel MA, Brown J, et al. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol. 2008;198(2):194.e1-194.e5.
5. Bonnin A, Goeden N, Chen K, et al. A transient placental source of serotonin for the fetal forebrain. Nature. 2011;472(7343):347-350.
6. Whitaker-Azmitia PM, Zhang X, Clarke C. Effects of gestational exposure to monoamine oxidase inhibitors in rats: preliminary behavioral and neurochemical studies. Neuropsychopharmacology. 1994;11(2):125-132.
7. Hadjikhani N. Serotonin, pregnancy and increased autism prevalence: is there a link? Med Hypotheses. 2010;74(5):880-883.
8. Le Strat Y, Dubertret C, Le Foll B. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord. 2011;135(1-3):128-138.
9. Walton GD, Ross LE, Stewart DE, et al. Decisional conflict among women considering antidepressant medication use in pregnancy. Arch Women Ment Health. 2014;17(6):493-501.
10. Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2015;20(6):727-734.
11. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68(11):1104-1112.
12. Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369(25):2406-2415.
13. Man KK, Tong HH, Wong LY, et al. Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies. Neurosci Biobehav Rev. 2015;49:82-89.
14. Gentile S. Prenatal antidepressant exposure and the risk of autism spectrum disorders in children: are we looking at the fall of Gods? J Affect Disord. 2015;182:132-137.
15. Wisner KL, Sit DK, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry. 2009;166(5):557-566.
16. Owen MJ. Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality. Br J Psychiatry. 2012;200(4):268-269.
17. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
18. von Elm E, Altman DG, Egger M, et al; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007;45(4):247-251.
19. Ross LE, Grigoriadis S, Mamisashvili L, et al. Quality assessment of observational studies in psychiatry: an example from perinatal psychiatric research. Int J Methods Psychiatr Res. 2011;20(4):224-234.
20. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.
21. Wells GA, Shea B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-analyses. Ottawa, ON: Department of Epidemiology and Community Medicine; 2003.
22. Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive metaanalysis. Br J Psychiatry. 2009;195(1):7-14.
23. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
24. Grigoriadis S, Vonderporten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ. 2014;348:f6932.
25. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
26. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206.
27. El Marroun H, White TJ, van der Knaap NJ, et al. Prenatal exposure to selective serotonin reuptake inhibitors and social responsiveness symptoms of autism: population-based study of young children. Br J Psychiatry. 2014;205(2):95-102.
28. Gidaya NB, Lee BK, Burstyn I, et al. In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder. J Autism Dev Disord. 2014;44(10):2558-2567.
29. Sørensen MJ, Grønborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol. 2013;5(1):449-459.
30. Harrington RA, Lee LC, Crum RM, et al. Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay. Pediatrics. 2014;133(5):e1241-e1248.
31. Rai D, Lee BK, Dalman C, et al. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based casecontrol study. BMJ. 2013;346:f2059.
32. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170(2):117-124.
33. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med. 2001;20(4):641-654.
34. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381(9875):1371-1379.
35. Ghaziuddin M, Ghaziuddin N, Greden J. Depression in persons with autism: implications for research and clinical care. J Autism Dev Disord. 2002;32(4):299-306.
36. Hollander E, King A, Delaney K, et al. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res. 2003;117(1):11-16.
37. De Long R. Autism and familial major mood disorder: are they related? J Neuropsychiatry Clin Neurosci. 2004;16(2):199-213.
38. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28(6):1186-1197.
39. Sandman CA, Wadhwa PD, Dunkel-Schetter C, et al. Psychobiological influences of stress and HPA regulation on the human fetus and infant birth outcomes. Ann N Y Acad Sci. 1994;739:198-210.
40. Howerton CL, Morgan CP, Fischer DB, et al. O-GlcNAc transferase (OGT) as a placental biomarker of maternal stress and reprogramming of CNS gene transcription in development. Proc Natl Acad Sci U S A. 2013;110(13):5169-5174.
41. Kinney DK, Munir KM, Crowley DJ, et al. Prenatal stress and risk for autism. Neurosci Biobehav Rev. 2008;32(8):1519-1532.
42. Levin M, Buznikov GA, Lauder JM. Of minds and embryos: left-right asymmetry and the serotonergic controls of pre-neural morphogenesis. Dev Neurosci. 2006;28(3):171-185.
43. Benes FM, Taylor JB, Cunningham MC. Convergence and plasticity of monoaminergic systems in the medial prefrontal cortex during the postnatal period: implications for the development of psychopathology. Cereb Cortex. 2000;10(10):1014-1027.
44. Vitalis T, Cases O, Passemard S, et al. Embryonic depletion of serotonin affects cortical development. Eur J Neurosci. 2007;26(2):331-344.
45. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr. 1961;58(3):315-320.
46. Mulder EJ, Anderson GM, Kema IP, et al. Platelet serotonin levels in pervasive developmental disorders and mental retardation: diagnostic group differences, within-group distribution, and behavioral correlates. J Am Acad Child Adolesc Psychiatry. 2004;43(4):491-499.
47. Dufour-Rainfray D, Vourc'h P, Tourlet S, et al. Fetal exposure to teratogens: evidence of genes involved in autism. Neurosci Biobehav Rev. 2011;35(5):1254-1265.
48. Larson MJ, Miller K, Fleming KJ. Treatment with antidepressant medications in private health plans. Adm Policy Ment Health. 2007;34(2):116-126.